These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 1092751)
1. Recent advances in the treatment of Parkinson's disease. Martocci RJ J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751 [No Abstract] [Full Text] [Related]
2. Choice of treatment in Parkinson's disease. Stern GM; Lees AJ Practitioner; 1977 Oct; 219(1312):537-41. PubMed ID: 594012 [No Abstract] [Full Text] [Related]
3. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)]. Hanzal F MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540 [TBL] [Abstract][Full Text] [Related]
8. Medical treatment of Parkinson's disease. Ahlskog JE Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977 [No Abstract] [Full Text] [Related]
9. Too many treatments for Parkinson's disease: how should they be used? Reynolds NC; Terry LC; Mark LP; Prieto TE; Mueller WR WMJ; 2000 Jun; 99(3):57-61, 43. PubMed ID: 10927984 [TBL] [Abstract][Full Text] [Related]
11. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. Fernandez HH; Odin P Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823 [TBL] [Abstract][Full Text] [Related]
12. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease. Barbeau A Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474 [No Abstract] [Full Text] [Related]
13. New drugs for Parkinson's disease. Med Lett Drugs Ther; 1976 Dec; 18(27):117-8. PubMed ID: 1004371 [No Abstract] [Full Text] [Related]
14. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Brannan T; Yahr MD Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264 [TBL] [Abstract][Full Text] [Related]
15. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340 [TBL] [Abstract][Full Text] [Related]
16. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings. Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761 [No Abstract] [Full Text] [Related]
17. Sinemet CR in Parkinson's disease. Pfeiffer RF; Wilken KE; Glaeske CS; Hofman R Nebr Med J; 1991 Jan; 76(1):8-10. PubMed ID: 1997878 [TBL] [Abstract][Full Text] [Related]
18. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Admani AK; Verma S; Cordingley GJ; Harris RI Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292 [TBL] [Abstract][Full Text] [Related]
19. [Therapy of Parkinson's disease. Practical criteria of treatment]. Casacchia M; Carolei A; Zamponi A; Agnoli A; Fazio C Recenti Prog Med; 1976 May; 60(5):567-84. PubMed ID: 14360 [No Abstract] [Full Text] [Related]
20. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Libman I; Gawel MJ; Riopelle RJ; Bouchard S Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]